Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Diabetic Lumbosacral Plexopathy Medication

  • Author: Divakara Kedlaya, MBBS; Chief Editor: Robert H Meier, III, MD  more...
 
Updated: Oct 20, 2015
 

Medication Summary

Intravenous human immunoglobulin (IVIg) may hasten recovery in patients with diabetic lumbosacral plexopathy, although this treatment has not yet been proven in controlled studies and remains controversial.[30, 31, 32] Other immunosuppressive agents, such as cyclophosphamide and methylprednisolone, are also thought to improve recovery. Kilfoyle et al studied treatment with pulsed methylprednisolone at 500 mg for 2 days every 2 weeks (instituted within 3 months of symptom onset) and noted significant improvement in pain and weakness in the majority of patients.[33]

Another study, by Dyck et al, suggested that methylprednisolone is effective against diabetic lumbosacral radiculoplexus neuropathy. The double-blind, placebo-controlled study involved 75 patients with the condition, who were randomized to a 12-week regimen of intravenous methylprednisolone or placebo.[34] Although the study’s primary outcome (time to improvement of neuropathy impairment score) was not significantly different between the 2 groups, patients treated with methylprednisolone reported significantly greater symptom improvement, particularly with regard to measures of pain and positive sensory symptoms.

However, a 2009 Cochrane review concluded that no evidence from randomized trials supported a recommendation for immunotherapy’s use in the treatment in diabetic lumbosacral plexopathy.[35] In 2012, an updated Cochrane review reported that supportive evidence was still lacking.[36]

Next

Blood Products

Class Summary

The administration of human immunoglobulins may improve the clinical and immunologic aspects of the disease. Blood products may decrease autoantibody production and increase solubilization and removal of immune complexes.

Immunoglobulins (Gamimune, Gammagard S/D, Sandimmune)

 

Immunoglobulin neutralizes circulating myelin antibodies through anti-idiotypic antibodies. In addition, it down-regulates proinflammatory cytokines, including interferon (IFN)-gamma; blocks Fc receptors on macrophages; suppresses inducer T-cells and B-cells and augments suppressor T-cells; blocks complement cascade; promotes remyelination; and may increase cerebrospinal fluid (CSF) levels of immunoglobulin (Ig) G (10%).

Previous
Next

Immunosuppressive Agents

Class Summary

Immunosuppressive agents such as cyclophosphamide, methylprednisolone, and prednisone may improve recovery.

Cyclophosphamide

 

Cyclophosphamide is a cyclic polypeptide that suppresses some humoral activity. It is chemically related to nitrogen mustards and is activated in the liver to its active metabolite, 4-hydroxycyclophosphamide, which alkylates the target sites in susceptible cells in an all-or-none–type reaction. When used in autoimmune diseases, the mechanism of action is thought to involve immunosuppression due to destruction of immune cells via DNA cross-linking.

Azathioprine (Imuran)

 

Azathioprine is an imidazolyl derivative of 6-mercaptopurine. It antagonizes purine metabolism and inhibits synthesis of DNA, RNA, and proteins. It works primarily on T cells and suppresses hypersensitivities of the cell-mediated type and causes variable alterations in antibody production.

Methylprednisolone (Medrol, Solu-Medrol)

 

Methylprednisolone is an immunosuppressant that decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing increased capillary permeability.

Prednisolone

 

Prednisone is an immunosuppressant that can be used for the treatment of autoimmune disorders. It may decrease inflammation by reversing increased capillary permeability and suppressing polymorphonuclear activity. It stabilizes lysosomal membranes and suppresses lymphocyte and antibody production.

Previous
Next

Tricyclic Antidepressants

Class Summary

These drugs have central and peripheral anticholinergic effects, as well as sedative effects, and block the active reuptake of norepinephrine and serotonin.

Amitriptyline

 

Amitriptyline is an oral analgesic for certain types of chronic pain. The usual adult dose ranges from 30-150 mg/d.

Nortriptyline (Pamelor)

 

Nortriptyline has demonstrated effectiveness in the treatment of chronic pain via inhibition of the reuptake of serotonin and/or norepinephrine by the presynaptic neuronal membrane. As a result, this drug increases the synaptic concentration of these neurotransmitters in the central nervous system (CNS). In addition, pharmacodynamic effects, such as the desensitization of adenyl cyclase and the down-regulation of beta-adrenergic receptors and serotonin receptors, appear to play a role in its mechanisms of action.

Doxepin (Silenor)

 

This agent inhibits histamine and acetylcholine activity and has proven useful in the treatment of various forms of depression associated with chronic and neuropathic pain.

Desipramine (Norpramin)

 

Desipramine may increase the synaptic concentration of norepinephrine in the CNS by inhibiting reuptake by presynaptic neuronal membrane. The drug may have effects in the desensitization of adenyl cyclase and in the downregulation of beta-adrenergic receptors and serotonin receptors.

Previous
Next

Antiepileptic Drugs

Class Summary

These agents are used for neuropathic pain.

Gabapentin (Neurontin)

 

Gabapentin has anticonvulsant properties and antineuralgic effects; however, its exact mechanism of action is unknown. The drug is structurally related to gamma-aminobutyric acid (GABA) but does not interact with GABA receptors. Titration to effect can take place over several days (300 mg on day 1, 300 mg bid on day 2, and 300 mg tid on day 3).

Pregabalin (Lyrica)

 

Pregabalin is a structural derivative of GABA. The mechanism of action is unknown. It binds with high affinity to the alpha2-delta site (a calcium channel subunit). It is FDA approved for neuropathic pain associated with diabetic peripheral neuropathy or postherpetic neuralgia and as adjunctive therapy in partial-onset seizures.

Previous
 
Contributor Information and Disclosures
Author

Divakara Kedlaya, MBBS Clinical Associate Professor, Department of Physical Medicine and Rehabilitation, Loma Linda University School of Medicine; Medical Director, Physical Medicine and Rehabilitation and Pain Management, St Mary Corwin Medical Center

Divakara Kedlaya, MBBS is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, Colorado Medical Society, American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Aishwarya Patil, MD Physiatrist (Rehabilitation Physician), Vice Chair, Immanuel Rehabilitation Center

Aishwarya Patil, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine, Association of Academic Physiatrists, Association of Physicians of India

Disclosure: Nothing to disclose.

Chief Editor

Robert H Meier, III, MD Director, Amputee Services of America; Active Medical Staff, Presbyterian/St Luke’s Hospital, Spalding Rehabilitation Hospital, Select Specialty Hospital; Consulting Staff, Kindred Hospital

Robert H Meier, III, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, Association of Academic Physiatrists

Disclosure: Nothing to disclose.

Additional Contributors

Teresa L Massagli, MD Professor of Rehabilitation Medicine, Adjunct Professor of Pediatrics, University of Washington School of Medicine

Teresa L Massagli, MD is a member of the following medical societies: Academy of Spinal Cord Injury Professionals, American Academy of Physical Medicine and Rehabilitation, Association of Academic Physiatrists

Disclosure: Nothing to disclose.

References
  1. Bruns L. Uberneuritsche lahmungen beim diabetes mellitus. Berl Klin Wochenschr. 1890. 27:509-15.

  2. GARLAND H. Diabetic amyotrophy. Br Med J. 1955 Nov 26. 2(4951):1287-90. [Medline]. [Full Text].

  3. Asbury AK. Proximal diabetic neuropathy. Ann Neurol. 1977 Sep. 2(3):179-80. [Medline].

  4. Locke S, Lawrence DG, Legg MA. Diabetic amyotrophy. Am J Med. 1963 Jun. 34:775-85. [Medline].

  5. Sander HW, Chokroverty S. Diabetic amyotrophy: current concepts. Semin Neurol. 1996 Jun. 16(2):173-8. [Medline].

  6. Tracy JA, Dyck PJ. The spectrum of diabetic neuropathies. Phys Med Rehabil Clin N Am. 2008 Feb. 19(1):1-26, v. [Medline]. [Full Text].

  7. Raff MC, Asbury AK. Ischemic mononeuropathy and mononeuropathy multiplex in diabetes mellitus. N Engl J Med. 1968 Jul 4. 279(1):17-21. [Medline].

  8. Taylor BV, Dunne JW. Diabetic amyotrophy progressing to severe quadriparesis. Muscle Nerve. 2004 Oct. 30(4):505-9. [Medline].

  9. Brown MJ, Asbury AK. Diabetic neuropathy. Ann Neurol. 1984 Jan. 15(1):2-12. [Medline].

  10. Williams IR, Mayer RF. Subacute proximal diabetic neuropathy. Neurology. 1976 Feb. 26(2):108-16. [Medline].

  11. Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology. 1999 Dec 10. 53(9):2113-21. [Medline].

  12. Harrison MJ, Casey EB. Diabetic amyotrophy. Br Med J. 1972 Jul 29. 3(5821):293. [Medline]. [Full Text].

  13. Pascoe MK, Low PA, Windebank AJ, Litchy WJ. Subacute diabetic proximal neuropathy. Mayo Clin Proc. 1997 Dec. 72(12):1123-32. [Medline].

  14. Kawamura N, Dyck PJ, Schmeichel AM, Engelstad JK, Low PA, Dyck PJ. Inflammatory mediators in diabetic and non-diabetic lumbosacral radiculoplexus neuropathy. Acta Neuropathol. 2008 Feb. 115(2):231-9. [Medline].

  15. Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve. 2002 Apr. 25(4):477-91. [Medline].

  16. Casey EB, Harrison MJ. Diabetic amyotrophy: a follow-up study. Br Med J. 1972 Mar 11. 1(5801):656-9. [Medline]. [Full Text].

  17. Bastron JA, Thomas JE. Diabetic polyradiculopathy: clinical and electromyographic findings in 105 patients. Mayo Clin Proc. 1981 Dec. 56(12):725-32. [Medline].

  18. Gulve EA. Exercise and glycemic control in diabetes: benefits, challenges, and adjustments to pharmacotherapy. Phys Ther. 2008 Nov. 88(11):1297-321. [Medline].

  19. Russell JW, Berent-Spillson A, Vincent AM, Freimann CL, Sullivan KA, Feldman EL. Oxidative injury and neuropathy in diabetes and impaired glucose tolerance. Neurobiol Dis. 2008 Jun. 30(3):420-9. [Medline]. [Full Text].

  20. Barohn RJ, Sahenk Z, Warmolts JR, Mendell JR. The Bruns-Garland syndrome (diabetic amyotrophy). Revisited 100 years later. Arch Neurol. 1991 Nov. 48(11):1130-5. [Medline].

  21. Gupta G, Massie R, Doherty TJ, et al. Diabetic Cranio-Cervico-Radiculoplexus Neuropathy. PM R. 2015 May 12. [Medline].

  22. O'Neill BJ, Flanders AE, Escandon SL, Tahmoush AJ. Treatable lumbosacral polyradiculitis masquerading as diabetic amyotrophy. J Neurol Sci. 1997 Oct 22. 151(2):223-5. [Medline].

  23. Matsuda N, Kobayashi S, Ugawa Y. [Skeletal muscle magnetic resonance imaging study in a patient with diabetic lumbosacral radiculoplexus neuropathy]. Rinsho Shinkeigaku. 2014. 54(9):751-4. [Medline].

  24. Deroide N, Bousson V, Mambre L, et al. Muscle MRI STIR signal intensity and atrophy are correlated to focal lower limb neuropathy severity. Eur Radiol. 2014 Sep 26. [Medline].

  25. Younger DS. Diabetic lumbosacral radiculoplexus neuropathy: a postmortem studied patient and review of the literature. J Neurol. 2011 Jul. 258(7):1364-7. [Medline].

  26. Tracy JA, Engelstad JK, Dyck PJ. Microvasculitis in diabetic lumbosacral radiculoplexus neuropathy. J Clin Neuromuscul Dis. 2009 Sep. 11(1):44-8. [Medline].

  27. Tataroglu C, Bicerol B, Kiylioglu N, Ozkul A, Akyol A. Proximal femoral conductions in patients with lumbosacral radiculoplexus neuropathy. Clin Neurol Neurosurg. 2007 Oct. 109(8):654-60. [Medline].

  28. Subramony SH, Wilbourn AJ. Diabetic proximal neuropathy. Clinical and electromyographic studies. J Neurol Sci. 1982 Feb. 53(2):293-304. [Medline].

  29. Kazamel M, Dyck PJ. Sensory manifestations of diabetic neuropathies: anatomical and clinical correlations. Prosthet Orthot Int. 2015 Feb. 39 (1):7-16. [Medline].

  30. Fernandes Filho JA, Nathan BM, Palmert MR, Katirji B. Diabetic amyotrophy in an adolescent responsive to intravenous immunoglobulin. Muscle Nerve. 2005 Dec. 32(6):818-20. [Medline].

  31. Kawagashira Y, Watanabe H, Oki Y, Iijima M, Koike H, Hattori N, et al. Intravenous immunoglobulin therapy markedly ameliorates muscle weakness and severe pain in proximal diabetic neuropathy. J Neurol Neurosurg Psychiatry. 2007 Aug. 78(8):899-901. [Medline]. [Full Text].

  32. Wada Y, Yanagihara C, Nishimura Y, Oka N. A case of diabetic amyotrophy with severe atrophy and weakness of shoulder girdle muscles showing good response to intravenous immune globulin. Diabetes Res Clin Pract. 2007 Jan. 75(1):107-10. [Medline].

  33. Kilfoyle D, Kelkar P, Parry GJ. Pulsed methylprednisolone is a safe and effective treatment for diabetic amyotrophy. J Clin Neuromuscul Dis. 2003 Jun. 4(4):168-70. [Medline].

  34. Dyck PJB, O’Brien P, Bosch EP, et al. The multi-center, double-blind controlled trial of IV methylprednisolone in diabetic lumbosacral radiculoplexus neuropathy. Neurology. Feb 2006. 66(5 Suppl 2):A191.

  35. Chan YC, Lo YL, Chan ES. Immunotherapy for diabetic amyotrophy. Cochrane Database Syst Rev. 2009 Jul 8. CD006521. [Medline].

  36. Chan YC, Lo YL, Chan ES. Immunotherapy for diabetic amyotrophy. Cochrane Database Syst Rev. 2012 Jun 13. 6:CD006521. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.